The Woodcock Effect: Is The New CDER Director Approving More Drugs?
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts, CEOs speculate whether Janet Woodcock's leadership has resulted in a better climate for drug approvals at FDA.
You may also be interested in...
Merck: Second “Not Approvable” Letter In Two Days – This Time, Cordaptive
FDA nixes name, too, for anti-cholesterol niacin/laropiprant combo.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?
US FDA Advisory Panels May Look Different Across Centers, Despite Efforts To Standardize Process
As FDA is readying to go back to in-person advisory committee meetings this fall, the centers have different ideas about how to use their expert panels.